Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY06006 versus EU-Prolia in postmenopausal osteoporosis
2024-513591-18-00Phase 3Completed
- Sponsor
- Boan Biotech
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of CMAB807 in postmenopausal osteoporosis (2 arms), sponsored by Boan Biotech. Started Apr 2023; status: completed.
02
Drugs
CMAB807
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on 2024-513591-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513591-18-00.